financetom
Business
financetom
/
Business
/
General Motors to Reassess Full-Year Outlook Amid Tariff Uncertainty; Beats First-Quarter Views
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
General Motors to Reassess Full-Year Outlook Amid Tariff Uncertainty; Beats First-Quarter Views
May 25, 2025 9:03 PM

12:36 PM EDT, 04/29/2025 (MT Newswires) -- General Motors ( GM ) plans to update its full-year outlook later in the week amid tariff uncertainty, while the automaker delivered better-than-expected first-quarter results on Tuesday.

The company postponed its earnings call to Thursday, citing "recent reports regarding updates to trade policy," GM said in a statement. During the call, it will discuss first-quarter results and its updated outlook for 2025 as the initial guidance "does not contemplate the potential impact of tariffs," according to the company.

US Commerce Secretary Howard Lutnick said on Tuesday that President Donald Trump is set to sign an order later in the day that is expected to ease the impact of 25% auto tariffs, Reuters reported.

"The future impact of tariffs could be significant," Chief Financial Officer Paul Jacobson said on a call with reporters, according to a separate Reuters report. "We're telling folks not to rely on the prior guidance, and we'll update when we have more information around tariffs."

Media reports showed that GM suspended its share buyback program until it has more clarity on the impact of US duties. The company didn't respond to MT Newswires' request for confirmation of the repurchase program's suspension and Jacobson's guidance remark.

In January, the automaker said it expected adjusted earnings to be in a range of $11 to $12 per share for the ongoing year. The current consensus on FactSet is for non-GAAP EPS of $9.95.

For the March quarter, GM's adjusted EPS rose to $2.78 from $2.62 last year, ahead of the Street's view for $2.68. Revenue increased 2.3% to $44.02 billion, surpassing the average analyst estimate of $43.23 billion.

Revenue in North America climbed to $37.39 billion from $36.1 billion in the 2024 quarter, while international sales declined to $2.43 billion from $3.08 billion. Vehicles sales rose to 1.45 million units from 1.35 million last year. Sales in the US market rose to 693,000 vehicles from 594,000.

Price: 46.51, Change: -0.73, Percent Change: -1.55

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Copyright 2023-2026 - www.financetom.com All Rights Reserved